Brought to you by 
Viracta closes Series C; new partner Salubris participates
06 Dec 2018
Executive Summary
Viracta Therapeutics Inc. closed its Series C round, led by a $10mm investment from new partner Shenzhen Salubris Pharmaceuticals Co. Ltd. Returning backers NantKwest, Latterell Venture Partners, and Forward Ventures also participated. Viracta is developing treatments for viral-related cancers, and concurrent with the Series C round, granted Salubris exclusive rights to develop and sell its lead candidate nanatinostat/valganciclovir in China for Epstein Barr virus-associated lymphomas, solid tumors, and for the prevention of EBV-associated post-transplant lymphoproliferative disorder. The project is currently in Phase Ib/II trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com